UroGen Pharma (NASDAQ:URGN) Now Covered by Scotiabank
Scotiabank started coverage on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research note released on Wednesday, Marketbeat reports. The brokerage issued a sector outperform rating and a $23.00 price target on the stock. URGN has been the topic of several other reports. HC Wainwright decreased their target price on shares of UroGen […]
Scotiabank started coverage on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research note released on Wednesday, Marketbeat reports. The brokerage issued a sector outperform rating and a $23.00 price target on the stock. URGN has been the topic of several other reports. HC Wainwright decreased their target price on shares of UroGen […]